CliffBio
biologic

Skytrofa

lonapegsomatropin-tcgd

Loss of exclusivityAugust 2033projected — 12-year biologic exclusivity estimate
CompanyAscendis Pharma Endocrinology Division A/S

Drug detail

Brand nameSkytrofa
Active ingredientlonapegsomatropin-tcgd
Strength3.6MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2021
Marketing statusRx

More from Ascendis Pharma Endocrinology Division A/S

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Skytrofa patent cliff — loss of exclusivity August 2033 | CliffBio